STA announces results from ABRAXANE plus gemcitabine phase III trial on pancreatic ca

[News]

Australian biopharmaceutical company Specialised Therapeutics Australia announces that a phase III clinical trial of world leading breast cancer drug ABRAXANE (nanoparticle albumin-bound paclitaxel) in combination with current standard of care gemcitabine in patients with advanced pancreatic cancer has demonstrated substantially improved survival times, with double the number of patients surviving two years.

More... (http://www.news-medical.net/news/20130123/STA-announces-results-from-ABRAXANE-plus-gemcitabine-phase-III-trial-on-pancreatic-cancer.aspx)